Standout Papers

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously... 2013 2026 2017 2021 531
  1. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial (2013)
    Thomas K. Waddell, Ian Chau et al. The Lancet Oncology

Immediate Impact

3 from Science/Nature 67 standout
Sub-graph 1 of 20

Citing Papers

Combination immunotherapy for hepatocellular carcinoma
2023 Standout
Pyroptosis‐Mediated Synergistic Photodynamic and Photothermal Immunotherapy Enabled by a Tumor‐Membrane‐Targeted Photosensitive Dimer
2023 Standout
2 intermediate papers

Works of Sarah Slater being referenced

Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME-HCC trial.
2022
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
2013 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Sarah Slater 510 632 313 36 1.1k
Lihu Gu 424 413 413 41 1000
Maria Ignez Braghiroli 570 296 224 57 877
Eun‐Kee Song 615 371 273 77 1.3k
Antonia Strippoli 516 422 318 65 1.0k
Daan J. Lips 500 488 470 41 948
R. Herrmann 652 345 224 45 1.1k
F Sellner 462 473 547 34 1.1k
David Watkins 725 437 286 80 1.4k
P. Preusser 651 955 527 46 1.3k
Keon Woo Park 692 591 379 41 1.2k

All Works

Loading papers...

Rankless by CCL
2026